Richard A. Larson to Drug Therapy, Combination
This is a "connection" page, showing publications Richard A. Larson has written about Drug Therapy, Combination.
Connection Strength
0.163
-
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012 Aug; 70(2):345-50.
Score: 0.090
-
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
Score: 0.035
-
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 12 27; 379(26):2517-2528.
Score: 0.035
-
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy. Blood. 1982 Oct; 60(4):877-87.
Score: 0.003